Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression. - Wikidata - wikimedia - TriplyDB

Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression.

Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression.

http://www.wikidata.org/entity/Q36220635

about

New viruses for cancer therapy: meeting clinical needs Trial Watch:: Oncolytic viruses for cancer therapy Trial Watch-Oncolytic viruses and cancer therapy Progress and problems with the use of suicide genes for targeted cancer therapy Oncolytic viruses: From bench to bedside with a focus on safety.Blockade of type I interferon (IFN) production by retroviral replicating vectors and reduced tumor cell responses to IFN likely contribute to tumor selectivity MicroRNA 142-3p attenuates spread of replicating retroviral vector in hematopoietic lineage-derived cells while maintaining an antiviral immune response.Tomato thymidine kinase-based suicide gene therapy for malignant glioma--an alternative for Herpes Simplex virus-1 thymidine kinase.Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector.Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model Increased sensitivity of glioma cells to 5-fluorocytosine following photo-chemical internalization enhanced nonviral transfection of the cytosine deaminase suicide gene Maintaining therapeutic activity in the operating room: compatibility of a gamma-retroviral replicating vector with clinical materials and biofluids.Advancements in the development of HIF-1α-activated protein switches for use in enzyme prodrug therapy.Photodynamic therapy enhances the efficacy of gene-directed enzyme prodrug therapy.EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-Fluorouracil-Mediated Cytotoxicity in Multiple Human Cancer Types.Extensive Replication of a Retroviral Replicating Vector Can Expand the A Bulge in the Encephalomyocarditis Virus Internal Ribosome Entry Site and Change Translation Efficiency of the Downstream Transgene.Convection-enhanced delivery improves distribution and efficacy of tumor-selective retroviral replicating vectors in a rodent brain tumor model Glioma virus therapies between bench and bedside.Combined alloreactive CTL cellular therapy with prodrug activator gene therapy in a model of breast cancer metastatic to the brain Retroviral Replicating Vector Delivery of miR-PDL1 Inhibits Immune Checkpoint PDL1 and Enhances Immune Responses In Vitro Clinical trials of viral therapy for malignant gliomas.Targeting tumor suppressor genes for cancer therapy.Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model.Evolving lessons on nanomaterial-coated viral vectors for local and systemic gene therapy.Oncolytic Immunotherapy for Treatment of Cancer.Gene Delivery in Neuro-Oncology.Retroviral replicating vector-mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity.Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models.Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model.Oncolytic virotherapy for gliomas: steps toward the future.Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma.A Retroviral Replicating Vector Encoding Cytosine Deaminase and 5-FC Induces Immune Memory in Metastatic Colorectal Cancer Models.Industry progress report on neuro-oncology: Biotech update 2013.Biotransporting Self-Assembled Nanofactories Using Polymer Vesicles with Molecular Permeability for Enzyme Prodrug Cancer Therapy.White paper on microbial anti-cancer therapy and prevention

P2860

Q24567699-8331E93B-E319-4841-90F3-E9A7E160D615 Q27021951-B61CFCFA-9644-4FD1-85B5-50BAC5F48F30 Q28072347-9B44311F-1D19-494F-8CB6-0E3689BA299E Q28262370-9CE62901-BE9C-49EF-8AB5-432D1A23BEF8 Q34044071-F97DD43E-5ED3-415D-9263-5933CF81581F Q34059493-FF27C54B-ACB5-47E4-BDBE-5BC2A80342B0 Q34063551-8F11CD74-E1BB-4C14-9926-166C2B3F0E4E Q34459264-14B94E14-B4D5-4C54-8C51-B1D172B7A74A Q34580201-14F85C89-CF49-446E-82E9-45874BCD07BF Q35077635-7B2600B4-78E5-4EA2-9A96-8CB5D7D73B0D Q35115061-7A34A10D-0929-417B-BC0D-6B5261F240EC Q35184172-D7AEEEB1-C776-438A-918D-97718410F991 Q35451950-E618D710-0B9E-4D4C-86F6-E03A462D95DB Q36297034-3158BFEB-BAD1-4A35-9FE3-8496339D7BEC Q36549443-2BFFF83D-295F-4481-A9BC-11EED06FDFFC Q36602123-D245E58D-A3B7-4F8F-88AE-5EBDA77EBF92 Q36806369-D30134BE-4DB1-45C5-844F-DA3D9C3055DA Q37069887-DF0B9C10-5B78-4D93-A21B-4B403747E951 Q37580510-E0EF5996-A611-4164-86A4-FD864287C00A Q37610904-C68BB864-4F46-4C73-BE9C-7625606E5F22 Q37718077-F1DBC38C-32C4-43C7-9974-64208842870F Q38153777-BBFEED74-92C6-45E4-B61B-F631589876D6 Q38601568-031A7D3E-EE85-4597-971B-D24767A28726 Q38733637-99BE2FCE-1280-4172-9226-D776ACDE9DEA Q38848060-4B8850DF-15F7-4EF0-B4EB-B752162DE685 Q38848223-41D6A232-DA3E-4B8D-9CDA-0A4DEDB9B80B Q40060078-151C7611-AFC9-481C-9C1E-E0AFDA5A399D Q40253347-1F24D16A-57A6-455C-A008-6BAF9C4CBA7D Q40760304-77427F26-A071-4A86-ACD6-36B54D6AC5AE Q42274901-FCB4B417-57A4-4804-9F4C-1AD2E38920C7 Q43436260-86A06C61-6946-4494-B64D-743358A46AFC Q45939742-09EB2C2F-CDB4-4E4E-97F4-BCC2895CE0C4 Q47739279-E8DEF832-163E-4220-9758-6453B25F2BFD Q47771059-0868FBA2-7D7D-416C-91C8-4F917DFB3241 Q47917107-9E5CCBEF-CE31-45C9-92F8-9A2FC66849FA Q56898750-6F33FDD8-A0B9-44B1-913D-8228EF525A85

P2860

Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression.

http://www.wikidata.org/entity/Q36220635

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Design and selection of Toca 5 ...... stability and gene expression.

@ast

Design and selection of Toca 5 ...... stability and gene expression.

@en

type

label

Design and selection of Toca 5 ...... stability and gene expression.

@ast

Design and selection of Toca 5 ...... stability and gene expression.

@en

prefLabel

Design and selection of Toca 5 ...... stability and gene expression.

@ast

Design and selection of Toca 5 ...... stability and gene expression.

@en

P1433

Q36220635-C0D6463D-1386-4898-9070-D1A47045C5C7

P1476

Q36220635-B1757D79-BE24-456F-A84A-736D635C7F38

P2093

Q36220635-0323311A-8FD2-4609-83F4-1E569C51BB1C

Q36220635-202FE9EC-0CBF-4CA9-A61D-3BCDA03A3EA4

Q36220635-33D1BBBD-6778-42E3-9CE2-7184CA93A558

Q36220635-381C8DC4-0BF4-4633-B127-A65DAB4745C9

Q36220635-4605E170-A42D-49BB-9132-BC20CC48A929

Q36220635-5EA5EFA4-B602-46E3-9CD4-729DD140FD42

Q36220635-6D7E2155-87D3-40C2-8192-3305D7614AEA

Q36220635-6E3C9E99-0AD1-42CD-9A15-90FBADBD2112

Q36220635-8839511B-50DF-4C94-AA2C-BE23FA8FC2BC

Q36220635-98B76F41-3E9A-4B40-BA6B-C85DA83605B6

P2860

Q36220635-08E6A967-9A3E-4F77-81E3-66C444808552

Q36220635-1622076D-2AF7-4CDC-9B88-ECF74868251D

Q36220635-303D9A44-D9B2-415B-858F-061E05436F32

Q36220635-4BD11F22-4C26-4C77-B169-AD111F67F55E

Q36220635-4BF6FCEC-FF6E-48E6-B8AC-4F322BDE9D33

Q36220635-4EBF5905-4361-4D9B-92F4-9F59ADFD4D8D

Q36220635-559E3788-706A-4DEF-B23D-CC8DD7EB9CCE

Q36220635-57CD7643-2AE6-4026-99DA-46161CD46745

Q36220635-57D96DF6-575A-40A2-B1FA-3F6D56861CD9

Q36220635-6C0AE9B4-C53A-4287-AEF4-EBAEBF499740

P304

Q36220635-138D5051-D39C-477C-AF2A-72D4AA2F0D66

P31

Q36220635-2E3E63A8-BDBD-4B8E-BE8E-E8672A1E8B41

P356

Q36220635-56CCBE26-8B53-4583-B935-5916C03345BD

P433

Q36220635-F653FF2E-571B-4868-9CEB-855704BB541B

P478

Q36220635-026B6F66-9BB5-411A-8B6E-764EA0305EDC

P50

Q36220635-AD38BD9D-AED1-4E1D-B0FE-161745779E6A

P577

Q36220635-A066FBF7-9093-49D9-9FED-46025DF6405E

P5875

Q36220635-F5B6236F-A1D7-4079-97C6-B22BE779B0E2

P698

Q36220635-A6D60CFE-53B2-4E72-AA06-F182BA12C791

P932

Q36220635-AC6E3177-B0A3-4ADE-B116-7714D83C24AE

P356

P1433

Molecular Therapy

P1476

Design and selection of Toca 5 ...... stability and gene expression.

@en

P2093

Akihito Inagaki

http://www.w3.org/2001/XMLSchema#string

Amy Lin

http://www.w3.org/2001/XMLSchema#string

Carlos Ibanez

http://www.w3.org/2001/XMLSchema#string

Cindy Burrascano

http://www.w3.org/2001/XMLSchema#string

Dan Lohse

http://www.w3.org/2001/XMLSchema#string

Dawn Jolson

http://www.w3.org/2001/XMLSchema#string

Douglas J Jolly

http://www.w3.org/2001/XMLSchema#string

Harry E Gruber

http://www.w3.org/2001/XMLSchema#string

Karin Amundson

http://www.w3.org/2001/XMLSchema#string

Kei Hiraoka

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular cloning and nucleotide sequence for the complete coding region of human UMP synthase

Pit2 assemblies at the cell surface are modulated by extracellular inorganic phosphate concentration

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Pharmacological studies with 5-fluorocytosine

Influence of vector design and host cell on the mechanism of recombination and emergence of mutant subpopulations of replicating retroviral vectors.

Phase II study of 5-fluorouracil and leucovorin in recurrent primary brain tumor.

A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers.

Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production.

Synergistic interaction between oncolytic viruses augments tumor killing.

A uniquely stable replication-competent retrovirus vector achieves efficient gene delivery in vitro and in solid tumors.

P304

1689-1698

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2012.83

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Christopher Logg

P577

2012-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224870769

http://www.w3.org/2001/XMLSchema#string

P698

22547150

http://www.w3.org/2001/XMLSchema#string

P932

3437576

http://www.w3.org/2001/XMLSchema#string